PMC8155744_01
Contrast-enhanced computed tomography showing a lobulated hypodense mass in
the spleen: (a) transaxial image; (b) coronal image.
10.1177_2050313X211016992-fig1.jpg
PMC8155744_01_10.1177_2050313X211016992-fig1.jpg
fig1-2050313X211016992
Computed tomography and magnetic resonance imaging indicated a huge lesion in the spleen (Figure 1).
(a) Whole-body 18F-fluorodeoxyglucose positron emission tomography
demonstrating high tracer accumulation only in the spleen. (b) Fused
positron emission tomography/computed tomography images of the cross section
of the spleen showed hot spot (maximum standard uptake value = 5.5).
10.1177_2050313X211016992-fig2.jpg
PMC8155744_01_10.1177_2050313X211016992-fig2.jpg
fig2-2050313X211016992
There was no abnormal increase in glucose metabolism in parts other than the spleen according to whole-body 18F-fluorodeoxyglucose positron emission tomography (Figure 2).
Macroscopic view of the resected spleen. A white-gray, well-defined mass
containing necrotic areas, 130 x 120 x 90 mm in size, showing an expansive
growth pattern in the spleen.
10.1177_2050313X211016992-fig3.jpg
PMC8155744_01_10.1177_2050313X211016992-fig3.jpg
fig3-2050313X211016992
The tumor was a white-gray, well-defined mass containing necrotic areas and measured approximately 130 x 120 x 90 mm with an expansive growth pattern (Figure 3).
Hematoxylin and eosin staining of the splenic tumor neoplastic cells showing
a papillary pattern with necrotic tissue and a psammoma body (arrow) (a,
x100). Pleomorphic and hyperchromatic nuclei were observed (b, x200).
10.1177_2050313X211016992-fig4.jpg
PMC8155744_01_10.1177_2050313X211016992-fig4.jpg
fig4-2050313X211016992
The representative features are shown in Figure 4.
Immunohistochemical staining of the tumor cells for cytokeratin 7 (a, x200),
cytokeratin 20 (b, x200), PAX-8 (c, x200), WT-1 (d, x200), p53 (e, x200),
and Ber-EP4 (f, x200).
10.1177_2050313X211016992-fig5.jpg
PMC8155744_01_10.1177_2050313X211016992-fig5.jpg
fig5-2050313X211016992
Ber-EP4 (Figure 5(f)) but negative for CK20 (Figure 5(b)), thyroid transcription factor-1, carcinoembryonic antigen, CD10, estrogen receptor, calretinin, D2-40, intelectin-1, and sialylated HEG1. Based on these findings, we diagnosed the tumor as a serous carcinoma.